13F Pro Quality Score

20.0/100

Rank #2,683 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

7.3/100

Profitability

10.9/100

Balance Sheet

15.1/100

Earnings Quality

30.0/100

Free Cash Flow

11.5/100

Institutional Flow

56.2/100

Revenue Scale

39.2/100

Dilution Risk

43.2/100

OPK Stock Analysis & AI Quality Score

AI stock analysis and institutional research for OPKO HEALTH, INC. (OPK), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores OPK at 20.0/100 on a 32-signal composite quality model, placing it at rank #2,683 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue growth (7.3) and profitability (10.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 43.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), OPKO HEALTH, INC. reports quarterly revenue of $124.2M, net income of $-54.8M, an operating margin of -41.1%. Top institutional holders of OPK by reported 13-F value include Rubric Capital Management, BlackRock,, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. OPK trades on the Nasdaq exchange and files with the SEC under CIK 944809. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate OPK daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for OPKO HEALTH, INC. directly from SEC EDGAR. OPKO HEALTH, INC.'s 13F Pro composite quality score has ranged between 8 and 61 since 2021, currently 20.0 — a declining long-term trajectory across 56 quarterly and live scoring snapshots.

Revenue

Q1 2026

$124.2M

Net Income

Q1 2026

$-54.8M

Free Cash Flow

Q1 2026

$-21.1M

Operating Margin

Q1 2026

-41.1%

D/E Ratio

Q1 2026

0.29

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-29.0% YoY
$713.1MFY 2024
FY20 $1.44BFY21 $1.77BFY22 $1.00BFY24 $713.1M

Net Income

+83.8% YoY
$-53.22BFY 2024
FY20 $30.6MFY21 $-30.14BFY22 $-328.40BFY24 $-53.22B

Operating Income

+32.8% YoY
$-152.1MFY 2024
FY20 $57.7MFY21 $18.8MFY22 $-226.3MFY24 $-152.1M

EPS (Diluted)

+82.6% YoY
$-0.08FY 2024
FY20 $0.05FY21 $-0.05FY22 $-0.46FY24 $-0.08

Total Assets

+1.5% YoY
$2.20BFY 2024
FY20 $2.47BFY21 $2.40BFY22 $2.17BFY24 $2.20B

Total Debt

+239.0% YoY
$874.4MFY 2024
FY20 $251.2MFY21 $205.3MFY22 $258.0MFY24 $874.4M

Op. Cash Flow

-92.8% YoY
$-183.5MFY 2024
FY20 $39.5MFY21 $38.3MFY22 $-95.2MFY24 $-183.5M

Get alerted when OPK's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for OPKO HEALTH, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Top Institutional Holders of OPK

Put OPK on your watchlist

Track score changes the day OPKO HEALTH, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is OPK a good stock to buy?

13F Pro's AI-powered analysis of OPKO HEALTH, INC. (OPK) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for OPK are available on the OPK stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own OPK?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling OPK. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of OPKO HEALTH, INC.'s investment landscape.